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Serum 25-hydroxyvitamiu P and parathyroid hormone in
patients with acute renal failure. The concentration of 25-hydroxy-
vitamin D (25-OH-D) in the serum of 18 patients with acute renal
failure was measured serially using a sensitive radiocompetitive
assay. In normal subjects, the mean concentration of serum 25-
OH-D was 16.6 ng/ml (range, 7.7 to 36 nglml). In patients with
acute renal failure, the mean serum 25-OH-D was 10.8 ng/ml on
admission, and after two weeks of oliguria, it decreased to a mean
of 6.0 ng/ml. Frequent sampling of blood and the subsequent assay
for 25-OFI-D have allowed for determination of the apparent serum
half-life of 25-OH-D, which averaged 5.6 days (range, 1.9 to 9.2) in
the 18 patients with acute renal failure. After this initial rapid fall,
the patients maintained low serum concentrations of 25-OH-D in
the course of acute renal failure, with a subsequent increase
following the recovery of normal kidney function. Low concentra-
tions of serum calcium, high inorganic phosphate, and slightly
increased levels of alkaline phosphatase activity were typically
found early in the course of acute renal failure and persisted during
oliguria and early polyuria. The serum immunoreactive parathy-
roid hormone was incrcased 2 to 4 times above the upper normal
limit in the first 4 to 8 days after the onset of renal failure, and it
further rose to an average of 2.7 nglml in the early polyuric stage,
in spite of a slight increase in serum calcium. It is postulated that
low concentrations of serum 25-OH-D may be a factor in the
development of the hypocalcemia and the secondary hyperpara-
thyroidism of acute renal failure. The significant fall in serum 25-
OH-D is probably due to an increased mctabolic clearance rate.
25-Hydroxyvitamine I) et hormone parathyroldienne sériques
chez les malades atteints d'insufllsance rénale aigué. La concentra-
tion sérique de 25-hydroxyvitamine D (25-OH-D) a été mesurée
plusieurs reprises chez 18 malades en insuffisance rénale aigue au
moyen d'une technique radio-competitive sensible. La concentra-
tion sérique moyenne de 25-OH-D chez les sujets normaux est de
16, 6 ng/mI et l'éventail des valeurs compris entre 7,7 et 36 ng/ml.
Chez les malades en insuffisance rdnale aigue Ia concentration
sérique moyenne de 25-OH-D a l'admission est de 10, 8 ng/ml et
elle baisse jusqu'à 6,0 nglml après deux semaines d'oligurie. Des
recueils de sang frequents ont permis la mesure de Ia demi-vie
apparente de 25-OH-D dans Ic serum, elle est de 5,6 jours en
moyenne (1,9 a 9,2) chez 18 malades en insuffisance rénale aiguë.
Après cette chute initiale rapide, les malades ont une concentra-
tion faible stable pendant l'évolution de l'insuflisance rénale aiguë
et une augmentation ultérieure lors de la récupération d'une fonc-
tion rénale normale. Des concentrations sériques faibles de cal-
cium, élevées de phosphate inorganique et légèrement augmentées
de phosphatases alealines sont observécs précocément au cours de
l'insuffisance rénale aiguë et persistent au cours de la phase oligu-
rique et au debut de Ia phase polyurique. La concentration sérique
d'hormone parathyroidienne immunoréactive est 2 a 4 fois Ia limite
supérieure de la normale dans les 4 a 8 premiers jours de
l'insuffisance rénale aiguë et elle augmente encore jusqu'h 2,7 ng/
ml au debut de Ia phase polyurique en dépit d'une augmentation,
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modérée, du calcium sérique. II est fait l'hypothèse que Ia concen-
tration sérique faible de 25-OH-D est un facteur de développement
de l'hypocalcémie et de l'hyperparathyroidisme secondaires de
l'insuffisance renale aigud. La diminution significative de Ia 25-
OFI-D sérique est probablement la consequence d'une augmenta-
tion de Ia clearance métabolique.
Disturbed calcium and phosphate metabolism with
secondary hyperparathyroidism are well known con-
sequences of chronic renal failure. Slatopolsky et al
[1] have suggested that hyperphosphatemia resulting
from decreased glomerular filtration rate is one of the
main causes of the hypocalcemia and secondary
hyperparathyroidism of chronic renal failure.
Although it has beea reported that this mechanism
operates in man 112], attempts to correct hypocalcem-
ia by administering phosphate binders (aluminum
hydroxide) to patients with chronic renal insufficien-
cy have been only partially successful. The use of a
high-calcium dialysate in combination with phos-
phate binders has produced limited success in cor-
recting secondary hyperparathyroidism and bone
abnormalities [3]. After Fraser and Kodicek [4]
demonstrated the essential role of the kidneys in the
synthesis of l,25(OH)2D3, Brickman et al [5] used
small dosages of the synthetic analogues of this pow-
erful vitamin D metabolite to produce an increase in
the concentration of serum calcium and a suppres-
sion of secondary hyperparathyroidism [5].
Data on the disturbances in calcium and phosphate
metabolism in acute renal failure have been compar-
atively limited. In previous studies, Kokot and Kus-
ka [6] found that hypocalcemia, hyperphosphatemia,
and increased parathyroid hormone levels are typical
findings in patients with acute renal failure. This
confirmed the earlier report by Massry et al [7], who
also documented the resistance to an infusion of
exogeneous parathyroid hormone given early in the
course of acute renal insufficiency. As no close cor-
relation between serum phosphorus and serum cal-
cium could be established in either of these studies
[6, 7], the cause of the hypocalcemia of acute renal
0085—2538/78/0013—0153 $01.60
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failure and the reason for the resistance to exoge-
neous parathyroid hormone has remained unclear.
Since relatively little knowledge is available con-
cerning the metabolism of vitamin D in acute renal
failure, the present study was undertaken to evaluate
systematically the relationships between serum cal-
cium, phosphate, parathyroid hormone, and 25-
hydroxyvitamin D in this clinical syndrome.
Methods
Eighteen patients with acute renal failure were
studied as they were admitted to the Department of
Nephrology, Silesian School of Medicine. The
patient population consisted of 12 men and 6 women;
their mean age was 38 years (range, 19 to 75). The
causes of acute renal failure were established as
follows: 7 patients had posttraumatic shock; 4 had
gram-negative septicemia; 2 women had puerperal
sepsis; one had gynecological sepsis; in 3 the causa-
tive factor was intoxication; and one patient had
bilateral renal artery thrombosis. The essential clini-
cal data of these patients are shown in Table 1.
Patients with simultaneous acute liver and kidney
insufficiency or with acute glomerulonephritis were
excluded from this study. No patient exhibited
symptoms of liver damage; and in all, the serum
bilirubin was below 1.2 mgIlOO ml, the serum glutam-
ic pyruvic transaminase (SGPT) was less than 1,500
nmoles per liter—1 per sec1, and gamma-glutamyl-
transpeptidase was below 70 nmoles per liter—1 per
sec—1. The mortality rate in this series was 28%.
The patients were admitted 4 to 8 days after the
onset of oliguria (according to the history obtained
from the patient or referring hospital), and all were
treated with hemodialysis (Travenol coil system)
three times a week during the oliguric phase. The
dialysis fluid contained (in mmoles/liter): sodium,
133; potassium, 3; calcium, 1.75; magnesium, 0.55;
chloride, 101; bicarbonate, 27; and acetate, 8.1. The
patients received a carbohydrate and fat-based diet
providing 2,200 kcal and 35 g of protein per day. The
average vitamin D content, as evaluated according to
nutritional tables [8], was 1,100 IU per week and was
derived mainly from eggs, milk, butter., and cheese.
The blood samples were taken at the time of admis-
sion to the hospital, and later they were taken before
each dialysis. For statistical analysis, the admission
values and the results obtained after 12 to 16 days of
oliguria were taken. Samples were obtained at least
once a week in the early polyuric phase (i.e., in the
first days of diuresis above 1 liter/day, when the
BUN was still over 40 mgIlOO ml), and in the late
polyuric phase of acute renal failure (recovery period
after the BUN concentration decreased to normal
values). Ten-milliliter blood samples were centri-
fuged immediately after clotting, and the sera were
divided into 5 portions and stored frozen at —20°C.
All analyses were performed serially for each
patient, to avoid interassay variation. The concentra-
tions of serum calcium, inorganic phosphate, total
protein, and alkaline phosphatase were determined
by methods previously reported [61. The serum
immunoreactive parathyroid hormone was measured
by radioimmunoassay [61, using purified bovine PTH
as a standard and 1251-bovine PTH (1—84) as tracer.
The antiserum used was heterogeneous and was
shown to combine with N-terminal and C-terminal
antigenic determinants. The detection limit was 50 pg
Table 1. Essential data of patients with oligu nc acute renal failure (ARF)
patient
no. Age Sex
Days after onset of ARE
Cause of ARFAdmission Urine output> 1,000 ml BUN normal
1 56 M 4 7 15 Posttraumatic shock
2 39 M 4 16 23 Posttraumatic shock
3 34 M 4 14 20 Posttraumatic shock
4 19 M 4 17 24 Posttraumatic shock
5 27 M 5 10 18 Posttraumatic shock
6 25 M 8 Died after 11 days of oliguna Posttraumatic shock
7 35 M 4 13 21 Posttraumatic shock
8 30 M 5 Died after 17 days of oliguria Gram-negative sepsis
9 60 F 8 12 19 Gram-negative sepsis
10 75 F 6 Died after 9 days of oliguria Gram-negative sepsis
11 52 F 7 27 died on the 33 day Gram-negative sepsis
12 29 F 4 14 17 Puerperal sepsis
13 31 F 4 17 22 Puerperal sepsis
14 25 F 7 16 20 Sepsis postsalpingectomy
15 26 M 8 15 20 Toxic (ethylene glycol)
16 52 M 6 10 15 Toxic (methanol)
17 19 M 5 15 20 Toxic (chromium)
18 50 M 7 Died after 16 days of oliguna Bilateral renal artery
thrombosis
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per assay tube, and the precision was 15%. In
normal subjects, the level of serum PTH was less
than 0.6 ng/ml.
The concentration of serum 25-hydroxyvitamin D
(25-OH-D) was measured by the competitive protein-
binding assay of Preece et al [91, with minor modifi-
cations. One-half milliliter of serum containing 20 pg
of 3H-25-OH-D was extracted with chloroform and
methanol, following the modified Bligh and Dyer
procedure [10]. The chloroform extracts were dried,
redis solved in diethylether/hexane (1:2, vollvol), and
transferred quantitatively to a silica gel (Merck,
Darmstadt; mesh 325) microcolumn (0.8 x 3 cm) and
washed with 7 ml of the same solvent. This eluate
was discarded. The fraction containing 25-OH-ID was
eluted from the column with 8 ml of diethylether
(more polar vitamin D metabolites may be next elut-
ed with methanol). The ether eluate was evaporated
to dryness and redissolved in 1.5 ml of ethanol. One-
half milliliter of this solution was counted for recov-
ery of the tracer added at the beginning of extraction,
which averaged 78% (SD, 4%). The total incubation
volume in the competitive protein-binding assay was
560d and consisted of the following: 50 pi ethanol,
containing either standard 25-OH-ID3 (0 to 3200 pg) or
the unknown purified sample (both in triplicate); lOp1
of ethanol, containing 60 pg [26/271-methyl-3H]-25-
hydroxycholecalciferol (specific activity, 12.2 Cu
mmole; Radiochemical Centre, Amersham); and
500pJ of 0.05 M barbital-sodium-acetate buffer (pH,
8.6), containing 0.2% gelatin and 1:16,000 diluted
rachitic rat serum as a source of 25-OH-ID-binding
protein. After mixing and overnight incubation at
4°C, separation of the free 25-OH-ID was performed
using dextran-coated charcoal (lOO6al buffer, contain-
ing 3 mg of Norit GSX [Clydesdale] and 0.3 mg of
dextran T-20,000 [Pharmacia, Uppsala] per assay
tube). The tubes were left for 30 mm and centrifuged
at 3,000 rpm for 10 mm at 4°C. Aliquots of superna-
tant (500 tl) were transferred to 14 ml of scintifluid
(0.5% PPO, 0.025% dimethyl-POPOP, 30% Triton X-
100 in toluene) and counted with an error of 1.5% in a
liquid scintillation counter (Packard). This assay
could detect 12 pg of 25-OH-ID per assay tube, and
the variation between assays was 10.7% for a sample
containing 12.7 ng/ml (N = 10). Twenty-five normal
adults studied throughout the year had values rang-
ing between 7.7 and 36.0 ng/ml (mean, 16.6 ng/ml).
Subjects with rickets or osteomalacia had values
below 4 ng/ml.
In 4 samples of sera from normal subjects and in 6
samples of sera obtained from patients with acute
renal failure in the oliguric phase, the 25-hydroxyvi-
tamin D-binding capacity was studied. Various dilu-
tions of human serum (1:1000 to 1:8000) in 0.05 M
barbital-sodium-acetate buffer (pH, 8.6) were incu-
bated with tracer amounts of tritiated 25-hydroxyvi-
tamin D3 (60 pg; specific activity, 12.2 Ci/mmole) in
triplicate small glass tubes (total incubation volume,
560 Ml). Each dilution of serum was also incubated
with tracer in presence of 3.2 ng of unlabelled 25-
OH-ID3; control tubes to correct for nonspecific bind-
ing were also included in the assay. After incubation
for 12 hr at 4°C, separation of the unbound sterol was
performed with dextran-coated charcoal (3 mg/tube),
the radioactivity of supematent was measured, and
the percentage of bound 25-OH-ID3 was calculated.
The statistical analysis was performed using Stu-
dent's t test wherever applicable, and the Wilcoxon
test for variables that deviate from normal distribu-
tion in human population [8].
Results
A high concentration of serum inorganic phos-
phate (normal range, 2.5 to 4.5 mg/l00 ml) was found
in 17 out of 18 patients on admission (mean, 9.4 mg/
100 ml) and persisted during the oliguric (mean, 8.0
mg/l00 ml) and the early polyuric phase (mean, 7.7
mg/l00 ml). In most patients studied, the serum
phosphate concentration was normal after recovery
of normal glomerular filtration rate (mean, 4.6 mg/
100 ml).
On admission, the mean serum calcium concentra-
tion was 7.5 mg1lOO ml. Normal values (8.8 to 10.7
mg/100 ml) were found in only 2 out of 18 patients, in
spite of the fact that a proportion of patients had
received a calcium chloride injection several hours
before being transported to the dialysis unit because
of the danger of hyperkalemia. The low serum cal-
cium concentration persisted throughout the oliguric
(mean, 7,9 mg/lOO ml) and early polyuric phases
(mean, 8.0 mg/lOO ml), but it was normal in most
patients during the late polyuric phase (Table 2, Figs.
1—4). The average total protein concentration was
6.0 g/l00 ml on admission, with a small increase
occurring in the subsequent course (Table 2). The
serum alkaline phosphatase activity (normal range,
20 to 80 lU/liter) was mildly elevated on admission
(Table 2), was increased after 2 weeks of oliguria to a
mean of 128 lU/liter (range, 50 to 255 lU/liter), and
had gradually retumed towards upper normal values
in the late polyuric phase.
The level of serum immunoreactive parathyroid
hormone (iPTH) was elevated in all patients studied
on admission, in the first days after the onset of
oliguria. The mean was 1.6 ng/ml, which represented
almost a three-fold increase over the upper normal
limit. In the subsequent course, in spite of a slight
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Table 2. The concentrations of serum total calcium, inorganic phosphate, alkaline phosphatase,
total protein, 25-OH-D, and immunoreactive parathyroid hormone (mean SEM and range)
Early
Admission Oliguria polyuria Late polyuria
Calcium, mg/I 00 ml 7.47 0.54
(5.9—8.8)
7.82 0.17
(6.4—9.1)
8.12 0.17
(7.2—9.6)
9.11 0.19
(7.9—9.9)
Inorganic phosphate, mg/IOU ml 9.41 0.91
(4.2—17.8)
8.02 0.64
(4.2—15.0)
7.75 0.77
(4.2—14.5)
4.61 0.53
(2.9—7.8)
Alkaline phosphatase, lU/liter 108.4 12.8
(42—274)
128.0 12.8
(50—255)
125.6 11.2
(57—250)
76.0 8.4
(52—118)
Total protein, g/100 ml 6.01 0.20
(5.0—8.0)
6.29 0.19
(5.5—8.0)
6.51 0.21
(5.5—8.0)
6.60 0.30
(5.8—8.0)
25-liydroxyvitamin D, ng/ml 10.83 0.91
(4.6—17.4)
6.00 0.49
(2.9—10.5)
4.48 0.38
(2.2—7.6)
9.93 1.12
(4.6—17.8)
Parathyroid hormone, ng/ml 1.56 0.10
(0.8—2.6)
2.31 0.18
(1.1—4.3)
2.70 0.40
(1.5—6.0)
0.54 0.09
(0.15—1.1)
Fig. 1. Patient no. I: The serum parathyroid hormone,
25-hydroxyvitamin D, and daily diuresis in the course
renal failure.
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Fig. 2. Patient no. 2.
higher mean iPTH concentration (2.7 ng/ml) was
found in the early polyuric phase. This progressive
rise in the level of serum iPTH could not be account-
ed for by parallel changes in serum calcium or phos-
phate concentrations (Table 2; Figs. 1—4). The mean
serum 25-OH-D concentration at admission was 10.8
ng/ml (range, 4.6 to 17.4 ng/ml), significantly lower
(P <0.05) when compared with that of 16.6 ngfml in
controls. At this time no patient had clearly abnor-
increase in the mean serum calcium and in spite of
dialysis treatment, the level of serum iPTH was still
rising in the oliguric phase (mean, 2.3 ng/ml); a still
I-
mal values (i.e., below 4 ng/ml). A further fall was
seen after two weeks of oliguria, and in most patients
the nadir for the 25-OH-D concentration was
observed in the early polyuric phase (mean, 4.5 ngl
ml; range, 2.2 to 7.6 ng!ml), 8 out of 14 patients
having values below 4 nglml (Figs. 1—4). Frequent
sampling of blood permitted a calculation of the
serum half-life of 25-OH-D. The results are shown in
Figure 5 and Table 3. The disappearance of the half-
life of serum 25-OH-D has been found to range
between 1.9 and 9.2 days (mean, 5.6 days) in the
oliguric phase. In the later course, the patients usual-
ly maintained a steady-state low concentration of
serum 25-OH-D throughout oliguric and polyuric
phases until the recovery of normal kidney function
when an upwards trend was seen.
Since the patients with acute renal failure were
EE(j
given a low protein diet with suboptimal vitamin D
content, we studied an additional control group of 9
subjects with conservatively treated chronic renal
failure (creatinine clearance between 5 and 16 ml!
mm). At the time of hospital admission, the average
serum 25-OH-D concentration was 8.6 1.7 (sEM)
ng!ml. After 3 weeks of hospital treatment with a low
protein diet, there was little if any change in the
serum 25-OH-D concentration (mean, 9.1 1.9 ng!
ml), although in contrast to patients with acute renal
failure, they usually had symptoms of uremic gas-
troenteritis and did not receive any supplemental
vitamin D.
Study of the serum 25-OH-D binding capacity. To
evaluate the possible influence of hemodialysis on
the serum 25-OH-D concentration, samples were
obtained before and after dialysis in 9 patients.
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Patient
no.
Apparent serum
25-OH-D half-life
days
Time of study
days after onset
1 1.9 4—7
2 5.6 4—11
3 6.0 4—12
4 6.3 4—11
5 6.9 5—17
6 2.0 8—10
7 5.9 4—13
8 3.8 5—13
9 5.2 7—10
10 5.8 6—8
11 4.6 7—10
12 2.9 4—8
13 9.2 4—19
14 8.7 7—12
15 7.2 8—14
16 6.4 6—12
17 9.2 5—14
18 2.9 7—10
Before dialysis, the mean 25-OH-D was 9.7 1.5 ngl
ml. After 8 hr of dialysis, this increased to 10.8 1.4
ng/ml, on the average by 11%. This represents proba-
bly a dehydration effect, as most patients lost 2 to 3
kg of body weight by ultrafiltration during dialysis.
25-OH-D circulates tightly bound to a specific serum
carrier protein having a mol wt of about 53,000 [11,
12]. The serum 25-OH-D binding capacity may be
estimated as being high enough to bind 100-fold larg-
er amounts of 25-OH-D than present in normal
human serum. We could not find much difference
between the 4 normal sera and 6 sera obtained from
Table 4. The serum 25-hydroxyvitamin D binding capacity in 4
normal subjects and 6 patients in the oligunc phase of acute renal
failure (ARF)
Final 25-OH- Percent binding of 25-OH-D3
D3 at serum dilution
concentration
=9.2 d Study No. serum in assay tube
group samples nglml 1:8000 1:4000 1:2000 1:1000
Normal 4 0.1
5.0
56±2
10±2
63±2
22±4
72±2
42±2
78±3
68±4
ARF 6 0.1
5.0
55±4
15±2
64±4
29±3
73±5
56±3
78±6
73±5
patients in the oliguric phase with a low 25-OH-D
content (Table 4).
Discussion
This study confirms the finding that disturbances
in calcium and phosphate metabolism occur in the
course of acute renal failure. Hyperphosphatemia
and hypocalcemia were found as early as the fourth
day of oliguria. Similar results were reported by
Massry et al [7]. The cause of hypocalcemia is
uncertain. Slatopoisky et al [1] provided evidence
that the first consequence of experimental renal fail-
ure is hyperphosphatemia, leading to hypocalcemia
and secondary hyperparathyroidism within hours.
This mechanism does not exclude the possibility that
the absence of 1 ,25-dihydroxyvitamin D production
in the kidney could contribute equally to a low serum
calcium concentration. The last factor could be oper-
ative in some patients with hypocalcemia despite the
presence of a normal or only slightly elevated serum
phosphate concentration.
The serum immunoreactive PTH was increased in
all patients on hospital admission 4 to 8 days after the
onset of oliguria. Interpretation of the serum iPTH
concentrations is made difficult by the fact that the
biologically inactive, carboxy-terminal fragments of
the hormone cross-react with our assay system.
There is a possibility that impaired degradation of
parathyroid hormone also contributes to the high
blood levels of immunoreactive hormone in the pres-
ence of renal disease. Parathyroid hormone has been
shown to circulate not only as the intact hormone but
also as carboxy-terminal and aminoterminal frag-
ments. In several studies [13, 14] it has been found
that synthetic N-terminal fragments are cleared from
plasma with a half-life of 3 to 5 minutes, while C-
terminal fragments without biological activity have
longer half-lives in the range of 1 to 2 hours. Hruska
et al [141 have reported that both half-lives are pro-
longed in the presence of renal failure by a factor of
1.5 to 2. Since steady-state serum concentration of
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Fig. 5. Decrease in serum 25-h ydroxyvitamin D concentration in
oliguric patients with acute renal failure (from left to right:
patients no. 1, 12,8, 2,4, 16,5, 13, and 17). The log (25-OH-D) vs.
time regression lines were calculated by the method of least
squares [8]. Time of study is given in Table 3.
Table 3. Serum 25-hydroxyvitamin D half-life in 18 patients with
acute renal failure
Mean t'/s = 5.6 days
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PTH would be expected after 5 to 7 half-life periods,
one may expect that changes in PTH secretion
should be reflected in the serum iPTH measured after
12 hr. A previous study [61 found that a dialysis-
induced rise in serum calcium of 8 hour's duration is
followed by a decrease in serum iPTH. Thus, the
reason for a further increase of serum iPTH after 2
weeks of oliguria in patients entering into the early
polyuric phase is difficult to explain on methodologic
grounds. The correlation coefficient for all paired
values of serum 25-OH-D and iPTH was r =
—0.3694 (P <0.01), and for serum iPTH and calcium
it was r = —0.2749 (P <0.05). This would imply that
higher levels of iPTH tend to occur together with low
25-OH-D values and with low serum calcium. From
Figs. 1—4 and Table 2, it follows that the peak serum
iPTH levels were found in the early polyuric phase;
this could not be explained by changes in serum
calcium or phosphate, but coincided with the nadir of
the 25-OH-D concentration. This is an intriguing
observation since it has been suggested before that
vitamin D metabolites might play a role in the control
of PTH secretion [5, 7, 15].
The significant fall in the serum 25-OH-D concen-
tration in the course of acute renal failure may be due
to decreased inflow of 25-OH-D into the circulating
plasma, or increased metabolic clearance rate, or
both. The dietary vitamin D content was suboptimal,
as the diet supplied only about 1,100 IU per week.
Except for one patient (patient no. 13) with septic
diarrhea, the group studied did not have symptoms
suggestive of malabsorption, and the diet was rea-
sonably well tolerated. Observation of 9 patients
with advanced chronic renal failure, conservatively
treated with low protein diet, did not show any
decrease in 25-OH-D over 3 weeks.
Although no patient in this study had symptoms of
liver damage, the possibility that acute renal failure
could block the conversion of vitamin D to 25-OH-D
is difficult to exclude. If this were the case, the
concentration of serum 25-OH-D would fall accord-
ing to its plasma clearance rate. Calculations of ser-
um 25-OH-D's half-life in individual patients (Fig. 5)
have shown an average of 5.6 days (range, 1.9 to 9.2
days). It has been reported in several studies [16, 17]
that the plasma turnover rate of 25-OH-D demon-
strates a half-life of 18 to 25 days in normal condi-
tions when using either labelled or unlabelled 25-OH-
D. Thus, the present data suggest an increased meta-
bolic clearance of 25-OH-D by a factor of 3 or 4 in
acute renal failure. If, however, the assumption of no
inflow of 25-OH-D does not hold, then the calculated
results may represent even an overestimation of real
plasma disappearance half-life. In this context, it is
interesting to note that Preece et a! [151 have shown
that because of suboptimal vit. D intake, Asian immi-
grants to Great Britain develop low 25-OH-D levels
and subclinical rickets or osteomalacia, not earlier
than 3 to 6 months after their arrival from India.
The cause of a decreased half-life of 25-OH-D in
plasma remains unclear. From possible factors we
have been able to exclude loss during hemodialysis,
as postdialysis serum 25-OH-D was 11% higher than
predialysis values. Pharmacokinetic considerations
would indicate that decreased binding by serum pro-
teins may result in lower levels of a drug. However,
the serum 25-OH-D binding capacity in oliguric
patients with low 25-OH-D concentration was not
different from normal subjects, as shown in Table 4.
It has been reported [18, 19] that 25-OH-D may be
taken up, probably by protein-binding, into many
tissues, of which skeletal muscle is quantitatively the
most important. This factor still remains to be clari-
fied. On the other hand, the observed decrease in the
half-life of serum 25-OH-D may also represent an
accentuation of plasma or tissue vitamin D degrading
pathways that normally exist but are abnormally
perpetuated by acute renal failure.
Any attempt to relate the low serum 25-OH-D
concentrations to the disturbed calcium and phos-
phate metabolism or to secondary hyperparathyroid-
ism remains conjectural at present. In this context
we would like to point out that one possible conse-
quence of the serum 25-OH-D deficient state might
be a decreased substrate availability for the synthesis
of I ,25-dihydroxy-vitamin D. Deficiency of 25-OH-D
and further metabolites of vitamin D may in turn lead
to decreased intestinal calcium absorption, second-
ary hyperparathyroidism or skeletal resistance to
parathyroid hormone, and may contribute to the
hypocalcemia of acute renal failure.
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